EA200800774A1 - STABLE FIRM SERTINDOL COMPOSITION - Google Patents

STABLE FIRM SERTINDOL COMPOSITION

Info

Publication number
EA200800774A1
EA200800774A1 EA200800774A EA200800774A EA200800774A1 EA 200800774 A1 EA200800774 A1 EA 200800774A1 EA 200800774 A EA200800774 A EA 200800774A EA 200800774 A EA200800774 A EA 200800774A EA 200800774 A1 EA200800774 A1 EA 200800774A1
Authority
EA
Eurasian Patent Office
Prior art keywords
sertindol
composition
stable firm
sertindole
pharmaceutical composition
Prior art date
Application number
EA200800774A
Other languages
Russian (ru)
Other versions
EA013167B1 (en
Inventor
Флемминг Энок Ольсен
Анна Равнхолт Кристенсен
Кен Лильегрен
Original Assignee
Х. Лундбекк А/С
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Х. Лундбекк А/С filed Critical Х. Лундбекк А/С
Publication of EA200800774A1 publication Critical patent/EA200800774A1/en
Publication of EA013167B1 publication Critical patent/EA013167B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Inorganic Chemistry (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Настоящее изобретение относится к фармацевтической композиции, содержащей сертиндол и защитное вещество, поглощающее излучение с длиной волны меньше 400 нм. Настоящее изобретение также относится к применению сертиндола для получения фармацевтической композиции, содержащей сертиндол и слой покрытия, содержащий указанное защитное вещество, такое как окись железа, для лечения шизофрении.The present invention relates to a pharmaceutical composition comprising sertindol and a protective substance that absorbs radiation with a wavelength less than 400 nm. The present invention also relates to the use of sertindole for preparing a pharmaceutical composition comprising sertindole and a coating layer containing said protective substance, such as iron oxide, for the treatment of schizophrenia.

EA200800774A 2005-09-08 2006-09-06 Stable solid formulation of sertindole EA013167B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200501255 2005-09-08
PCT/DK2006/050038 WO2007065448A1 (en) 2005-09-08 2006-09-06 Stable solid formulation of sertindole

Publications (2)

Publication Number Publication Date
EA200800774A1 true EA200800774A1 (en) 2008-06-30
EA013167B1 EA013167B1 (en) 2010-02-26

Family

ID=37697999

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200800774A EA013167B1 (en) 2005-09-08 2006-09-06 Stable solid formulation of sertindole

Country Status (17)

Country Link
EP (1) EP1924261A1 (en)
JP (1) JP2009507051A (en)
KR (1) KR20080042102A (en)
CN (1) CN101257906A (en)
AR (1) AR056475A1 (en)
AU (1) AU2006322460A1 (en)
BR (1) BRPI0615630A2 (en)
CA (1) CA2621866A1 (en)
EA (1) EA013167B1 (en)
IL (1) IL189541A0 (en)
MX (1) MX2008002290A (en)
NO (1) NO20081721L (en)
NZ (1) NZ565330A (en)
TW (1) TW200738239A (en)
UA (1) UA97349C2 (en)
WO (1) WO2007065448A1 (en)
ZA (1) ZA200801169B (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI320783B (en) 2005-04-14 2010-02-21 Otsuka Pharma Co Ltd Heterocyclic compound
CN102300563A (en) * 2009-01-29 2011-12-28 大日本住友制药株式会社 Orally disintegrating tablet having inner core
FR2943061B1 (en) * 2009-03-13 2011-02-25 Rhodia Operations ORGANOPHOSPHORUS COMPOUNDS, CATALYTIC SYSTEMS COMPRISING THESE COMPOUNDS, AND HYDROCYANATION OR HYDROFORMYLATION PROCESS USING THESE CATALYTIC SYSTEMS
US8883823B2 (en) 2012-07-16 2014-11-11 Fibrogen, Inc. Crystalline forms of a prolyl hydroxylase inhibitor
RS57795B1 (en) 2012-07-16 2018-12-31 Fibrogen Inc Crystalline forms of a prolyl hydroxylase inhibitor
KR20210104173A (en) 2013-06-06 2021-08-24 피브로겐, 인크. Pharmaceutical formulations of a hif hydroxylase inhibitor
CN105636585B (en) 2013-11-19 2020-02-07 西佳技术公司 Rehydration of micronized tecovirimat monohydrate
JP2018172361A (en) * 2016-10-14 2018-11-08 大原薬品工業株式会社 Solid preparation containing duloxetine, having improved light stability

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04346929A (en) * 1991-05-22 1992-12-02 Takada Seiyaku Kk Bromocriptine mesylate preparation having stability to light
JP2000507544A (en) * 1996-03-25 2000-06-20 イーライ・リリー・アンド・カンパニー How to treat pain
ZA973433B (en) * 1996-04-24 1997-12-10 Shionogi & Co A sertindole-containing preparation and a method for producing the same.
ZA977967B (en) * 1996-09-23 1999-03-04 Lilly Co Eli Combination therapy for treatment of psychoses

Also Published As

Publication number Publication date
EA013167B1 (en) 2010-02-26
AR056475A1 (en) 2007-10-10
IL189541A0 (en) 2008-08-07
UA97349C2 (en) 2012-02-10
AU2006322460A1 (en) 2007-06-14
WO2007065448A1 (en) 2007-06-14
NO20081721L (en) 2008-04-08
CA2621866A1 (en) 2007-06-14
NZ565330A (en) 2011-06-30
KR20080042102A (en) 2008-05-14
CN101257906A (en) 2008-09-03
EP1924261A1 (en) 2008-05-28
MX2008002290A (en) 2008-03-14
ZA200801169B (en) 2010-07-28
TW200738239A (en) 2007-10-16
JP2009507051A (en) 2009-02-19
BRPI0615630A2 (en) 2016-11-16

Similar Documents

Publication Publication Date Title
EA200800774A1 (en) STABLE FIRM SERTINDOL COMPOSITION
AR112816A2 (en) COMPOUNDS THAT INHIBIT THE BINDING OF SMAC PROTEIN TO THE PROTEIN INHIBITOR OF APOPTOSIS (IAP)
NO20074044L (en) Meleimide derivatives, pharmaceutical preparations and methods for the treatment of cancer
WO2006107451A3 (en) Honokiol derivatives for the treatment of proliferative disorders
MX2009010034A (en) Substituted pyrimidodiazepines useful as plk1 inhibitors.
EA200870415A1 (en) QUINAZOLINS TO INHIBIT PDK 1
MX2007002398A (en) New pharmaceutical compositions for the treatment of cancer.
WO2008097640A8 (en) Triazole compounds that are useful in the treatment of proliferative disorders, such as cancer
UA107783C2 (en) Isoindoline compounds for use in treating cancer
UY29246A1 (en) NEW COMPOUNDS
DK1951729T3 (en) OXYGEN BONDED PYRIMIDINE DERIVATIVES
BRPI0915084B8 (en) compound, and, pharmaceutical composition
CL2008003593A1 (en) Isoxazolo-pyridazine derived compounds; preparation procedure; pharmaceutical composition comprising said compound; and use of the compound in the treatment of cognitive disorders such as Alzheimer's
MX2010003365A (en) Thiazol derivatives for treating cancer.
CL2004001069A1 (en) COMPOUNDS DERIVED FROM 1-BENZOIL-ISOQUINOLINAS SUBSTITUTED; PREPARATION PROCEDURE, PHARMACEUTICAL COMPOSITION; AND USE FOR THE TREATMENT OR PROFILAXIS OF TYPE II DIABETES.
CL2007000161A1 (en) COMPOUNDS DERIVED FROM SUBSTITUTED 2,4-DIOXOIMIDAZOLIDINE, INHIBITORS OF KINE PROTEINS; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT OF DISEASES SUCH AS CANCER.
EA200802364A1 (en) COMPOSITION FOR SKIN CARE AND ITS APPLICATION
EA200970916A1 (en) COMPOUNDS 5,6-DIGIDRO-1N-PYRIDIN-2-SHE
EA201001196A1 (en) 4-PYRIDINONE COMPOUNDS AND THEIR APPLICATION FOR CANCER TREATMENT
BR0318278A (en) aminocyclohexyl ether compounds and uses thereof
CL2008000021A1 (en) Compounds derived from 2,4-dianilinopyrimidines, protein kinase inhibitors; preparation procedure; pharmaceutical composition; and use for the treatment or prevention of inflammatory diseases, diabetes, and cancer.
CL2009000119A1 (en) Compounds derived from substituted amino-benzimidazoles; pharmaceutical composition; and its use in the treatment of Alzheimer's.
CL2008003472A1 (en) Compounds derived from 5- [3,3,3-trifluoro-2-hydroxy-1-arylpropyl) amino] -1h-quinolin-2-one, process for their preparation, intermediate compounds, pharmaceutical composition comprising said compound ; Pharmaceutical combination, and its uses in the treatment of inflammatory diseases.
MX2009012920A (en) Compounds with 7-member cycle and the pharmaceutical use thereof for preventing and treating diabetes and metabolism syndrome.
ATE497760T1 (en) FILM COVER FOR TABLETS AND CAPLETTES

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KZ KG MD TJ TM